Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Dow
Express Scripts
Mallinckrodt
Baxter

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Sargramostim

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Sargramostim: Sponsors, patents, clinical trial progress

Sargramostim is an investigational drug.

There have been 261 clinical trials for Sargramostim. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2011.

The most common disease conditions in clinical trials are Leukemia, Lymphoma, and Multiple Myeloma. The leading clinical trial sponsors are National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Bayer.

There are one hundred and four US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Sargramostim
TitleSponsorPhase
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate CancerMadison Vaccines, IncPhase 2
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate CancerMerck Sharp & Dohme Corp.Phase 2
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate CancerProstate Cancer FoundationPhase 2

See all Sargramostim clinical trials

Clinical Trial Summary for Sargramostim

Top disease conditions for Sargramostim
Top clinical trial sponsors for Sargramostim

See all Sargramostim clinical trials

US Patents for Sargramostim

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sargramostim   See Pricing Trilayer coated pharmaceutical packaging SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)   See Pricing
Sargramostim   See Pricing TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) YALE UNIVERSITY (New Haven, CT)   See Pricing
Sargramostim   See Pricing Compositions comprising serum albumin and p53 peptides fusion proteins University of the Sciences of Philadelphia (Philadelphia, PA)   See Pricing
Sargramostim   See Pricing Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease Reponex Pharmaceuticals A/S (Horsholm, DK)   See Pricing
Sargramostim   See Pricing Synthetic antibody mimetic compounds (SYAMS) targeting cancer, especially prostate cancer YALE UNIVERSITY (New Haven, CT)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sargramostim

Drugname Country Document Number Estimated Expiration Related US Patent
Sargramostim Argentina 082615 2030-08-09   See Pricing
Sargramostim Australia 2010249031 2030-05-12   See Pricing
Sargramostim Australia 2010249033 2030-05-12   See Pricing
Sargramostim Australia 2011252925 2030-05-12   See Pricing
Sargramostim Australia 2012318242 2030-05-12   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKesson
Merck
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.